(TheDeal) -- AstraZeneca plc is waving good-bye to its gastrointestinal research operations, spinning its out into a standalone company. Dubbed Albireo, the new company is also the recipient of a $27 million venture capital round led by Nomura Phase4 Ventures, with contributions from TVM Capital and Scottish Widows Investment Partnership. And the initial funding is only the first part of what the company expects to be a $40 million financing.
